<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAE</journal-id>
<journal-id journal-id-type="hwp">sptae</journal-id>
<journal-title>Therapeutic Advances in Endocrinology and Metabolism</journal-title>
<issn pub-type="ppub">2042-0188</issn>
<issn pub-type="epub">2042-0196</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2042018812469645</article-id>
<article-id pub-id-type="publisher-id">10.1177_2042018812469645</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories>
<title-group>
<article-title>Diabetes and the elderly brain: sweet memories?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Samaras</surname><given-names>Katherine</given-names></name>
<aff id="aff1-2042018812469645">Diabetes and Obesity Program, Garvan Institute of Medical Research, Department of Endocrinology, St Vincent’s Hospital, 384 Victoria St, Darlinghurst, NSW 2010, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Sachdev</surname><given-names>Perminder S.</given-names></name>
<aff id="aff2-2042018812469645">Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Neuropsychiatric Institute, Prince of Wales Hospital, Randwick, NSW, Australia</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2042018812469645"><email>k.samaras@garvan.org.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>6</issue>
<fpage>189</fpage>
<lpage>196</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Type 2 diabetes is common in older people and is associated with higher risk of both vascular dementia and Alzheimer’s disease. This review examines the evidence for increased risk of dementia and mild cognitive impairment in patients with diabetes and the role of potential confounders. The relationship of diabetes and impaired fasting glucose with brain structure is also reviewed, focusing on longitudinal studies in older people. The pathophysiology underlying cognitive change in type 2 diabetes is examined with reference to vascular disease, hypoglycaemia, inflammation and insulin levels. Implications for clinical care in older people with diabetes are discussed, with a recommendation for cognitive evaluation as a routine part of end-organ, diabetes complication review.</p>
</abstract>
<kwd-group>
<kwd>Brain</kwd>
<kwd>brain volume</kwd>
<kwd>cognition</kwd>
<kwd>dementia</kwd>
<kwd>diabetes</kwd>
<kwd>glucose</kwd>
<kwd>impaired fasting glucose</kwd>
<kwd>inflammation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2042018812469645" sec-type="intro">
<title>Introduction</title>
<p>The ability to think clearly and make independent and appropriate decisions concerning self and others independently is something we usually take for granted. Many patients with diabetes, as they enter early old age, become concerned about their cognitive health. They often resort to the consumption of various supplements purported to slow cognitive decline, and may take up pursuits such as bridge and mathematical games as cognitive exercises to bolster neural activity and agility. Cognitive health of patients with diabetes is as much a concern for clinicians, not only because of the impact on a patient’s quality of life, but also because benchmarked diabetes care places expectations on the ability for self-directed care and diabetes decision making. It is timely to review the evidence for the extent by which diabetes affects cognition and brain structure in older people.</p>
<p>Type 2 diabetes mellitus (diabetes) is a common disease in older people, affecting about 30% of people aged 65–85 [<xref ref-type="bibr" rid="bibr50-2042018812469645">Steinman <italic>et al.</italic> 2012</xref>]. High diabetes rates are due to the environmental exposures of overnutrition and sedentariness, but also ageing of the population. In parallel, the prevalence of complex diseases such as dementia has also risen [<xref ref-type="bibr" rid="bibr2-2042018812469645">Alzheimer’s Disease International, 2011</xref>]. Advances in healthcare in developed countries have translated to longer survival of people with diabetes due to effective treatment of infectious disease, cardiovascular disease, some cancers and diabetic complications. The classic microvascular diabetic complications of nephropathy, retinopathy and peripheral neuropathy are well known outcomes of hyperglycaemia. Other clinically relevant complications such as macrovascular disease, diabetic cardiomyopathy and dementia impact substantially on health outcomes. More critically, these consequences of diabetes may overtake or dictate future clinical care priorities.</p>
<p>As a consequence, the natural history of type 2 diabetes in the twenty-first century developed world appears to be changing as more of the population reaches advanced years with long-term, treated diabetes that has benefited from improved interventions and vascular risk factor management. It is relevant to consider the intersection of diabetes (and its glycaemic, vascular, metabolic and inflammatory milieu) with the brain in the elderly. There is abundant evidence that diabetes detrimentally affects brain structure and function, across a spectrum from mild cognitive decline and impairment, through to dementia. Diabetes is currently considered to account for 6–8% of all cases of dementia in older people [<xref ref-type="bibr" rid="bibr27-2042018812469645">Kloppenborg <italic>et al.</italic> 2008</xref>]. Increasingly, there have been calls to recognize the brain as a target of end-organ damage in diabetes [<xref ref-type="bibr" rid="bibr51-2042018812469645">Strachan, 2011</xref>] and for recognition of a central diabetic encephalopathy or neuropathy [<xref ref-type="bibr" rid="bibr47-2042018812469645">Sima, 2010</xref>]. This review summarizes the evidence for changes in brain function and structure in type 2 diabetes mellitus.</p>
</sec>
<sec id="section2-2042018812469645">
<title>Diabetes and dementia</title>
<p>Studies published in the 1980s suggested that diabetes was less prevalent in Alzheimer’s disease [<xref ref-type="bibr" rid="bibr9-2042018812469645">Bucht <italic>et al.</italic> 1983</xref>; <xref ref-type="bibr" rid="bibr59-2042018812469645">Wolf-Klein <italic>et al.</italic> 1988</xref>], now explained by the likelihood of survival bias. A number of prospective observational studies since then have consistently reported an association between type 2 diabetes mellitus and dementia, showing that diabetes increased dementia risk 1.3–3.4 fold [<xref ref-type="bibr" rid="bibr5-2042018812469645">Biessels <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr52-2042018812469645">Strachan <italic>et al.</italic> 2011</xref>], as reviewed systemically elsewhere [<xref ref-type="bibr" rid="bibr5-2042018812469645">Biessels <italic>et al.</italic> 2006</xref>]. It is relevant to note that differences in dementia risk have been found in observational studies, depending on whether the cohort was in mid life or older and the type of dementia examined [<xref ref-type="bibr" rid="bibr5-2042018812469645">Biessels <italic>et al.</italic> 2006</xref>].</p>
<p>As diabetes is accompanied by increased vascular risk, it is relevant to focus on those longitudinal studies that have examined diabetes and dementia risk in older people but also included vascular risk factors as covariates. Representative studies that illustrate dementia risk after adjustment of important vascular risk factors known to increase dementia risk are summarized in <xref ref-type="table" rid="table1-2042018812469645">Table 1</xref>. In evaluating the results of these studies as a whole, it is important to note the methods of case ascertainment for both diabetes and dementia. All studies assessed for dementia at baseline and follow up, in one instance by medical record examination [<xref ref-type="bibr" rid="bibr25-2042018812469645">Hassing <italic>et al.</italic> 2002</xref>] and in others by initially screening for cognitive impairment and then performing a diagnostic assessment [<xref ref-type="bibr" rid="bibr31-2042018812469645">Luchsinger <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr32-2042018812469645">MacKnight <italic>et al.</italic> 2002</xref>; <xref ref-type="bibr" rid="bibr40-2042018812469645">Peila <italic>et al.</italic> 2002</xref>; <xref ref-type="bibr" rid="bibr60-2042018812469645">Xu <italic>et al.</italic> 2004</xref>]. In all studies, dementia diagnosis was confirmed by consensus within a central committee of experts. Consistent diagnostic criteria for dementia were applied from either the <italic>Diagnostic and Statistical Manual of Mental Disorders</italic>, 3rd edition [<xref ref-type="bibr" rid="bibr3-2042018812469645">American Psychiatric Association, 1980</xref>] or the fourth edition [<xref ref-type="bibr" rid="bibr4-2042018812469645">American Psychiatric Association, 1994</xref>]. A diagnosis of Alzheimer’s disease was based on the National Institute of Neurological and Communicative Diseases and Stroke and the Alzheimer’s Disease and Related Disorders Association [<xref ref-type="bibr" rid="bibr36-2042018812469645">McKhann <italic>et al.</italic> 1984</xref>] and vascular dementia by the National Institute of Neurological and Communicative Diseases and Stroke and the Association Internationale pour la Recherche et L’Ensignment en Neurosciences criteria [<xref ref-type="bibr" rid="bibr44-2042018812469645">Roman <italic>et al.</italic> 1993</xref>]. Diabetes was assessed by fasting glucose and oral glucose tolerance testing in only one study [<xref ref-type="bibr" rid="bibr40-2042018812469645">Peila <italic>et al.</italic> 2002</xref>]; one study performed random glucose levels [<xref ref-type="bibr" rid="bibr60-2042018812469645">Xu <italic>et al.</italic> 2004</xref>] and three studies relied on history and medications for diabetes ascertainment [<xref ref-type="bibr" rid="bibr25-2042018812469645">Hassing <italic>et al.</italic> 2002</xref>; <xref ref-type="bibr" rid="bibr31-2042018812469645">Luchsinger <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr32-2042018812469645">MacKnight <italic>et al.</italic> 2002</xref>]. With undiagnosed diabetes estimated at 30% in older people [<xref ref-type="bibr" rid="bibr53-2042018812469645">Thomas <italic>et al.</italic> 2005</xref>], misclassification of undiagnosed diabetes into the control group might underestimate the impact of diabetes on dementia risk. Further, dropout rates were substantial in these studies, being up to 39%. Even with these limitations, these studies consistently show a 2.0–3.4-fold increased risk of vascular dementia and a 1.8–2.0-fold increased risk of Alzheimer’s disease in older people with diabetes. For completeness, other longitudinal studies also show increased risk of dementia in diabetes, but they are not presented here because of a lack of vascular risk adjustment [<xref ref-type="bibr" rid="bibr1-2042018812469645">Arvanitakis <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr7-2042018812469645">Brayne <italic>et al.</italic> 1998</xref>; <xref ref-type="bibr" rid="bibr38-2042018812469645">Ott <italic>et al.</italic> 1999</xref>; <xref ref-type="bibr" rid="bibr65-2042018812469645">Yoshitake <italic>et al.</italic> 1995</xref>].</p>
<table-wrap id="table1-2042018812469645" position="float">
<label>Table 1.</label>
<caption>
<p>Type 2 diabetes and dementia risk in longitudinal observational studies, after adjusting for vascular risk factors.</p>
</caption>
<graphic alternate-form-of="table1-2042018812469645" xlink:href="10.1177_2042018812469645-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Author</th>
<th align="left">Source</th>
<th align="left">Age at base (years)</th>
<th align="left">Men (%)</th>
<th align="left"><italic>N</italic> at FU (% diabetes)</th>
<th align="left">FU</th>
<th align="left">Diabetes method</th>
<th align="left">Dropout rate (%)</th>
<th align="left">All dementia risk<xref ref-type="table-fn" rid="table-fn1-2042018812469645">*</xref> (95% CI)</th>
<th align="left">Vascular dementia risk<xref ref-type="table-fn" rid="table-fn1-2042018812469645">*</xref> (95% CI)</th>
<th align="left">Alzheimer’s dementia risk<xref ref-type="table-fn" rid="table-fn1-2042018812469645">*</xref> (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><xref ref-type="bibr" rid="bibr40-2042018812469645">Peila <italic>et al.</italic> [2002]</xref></td>
<td>USA</td>
<td>77</td>
<td>100</td>
<td>2574 (35%)</td>
<td>2.9</td>
<td>FGL, OGTT</td>
<td>27</td>
<td>1.5 (1.0–2.2)</td>
<td>2.3 (1.1–5.0)</td>
<td>1.8 (1.1–2.9)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr32-2042018812469645">MacKnight <italic>et al.</italic> [2002]</xref></td>
<td>Canada</td>
<td>76</td>
<td>39</td>
<td>5574 (9.1%)</td>
<td>5.0</td>
<td>History</td>
<td>39</td>
<td>1.3 (0.9–1.8)</td>
<td>2.0 (1.2–3.6)</td>
<td>1.3 (0.8–3.0)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr60-2042018812469645">Xu <italic>et al.</italic> [2004]</xref></td>
<td>Sweden</td>
<td>81</td>
<td>25</td>
<td>1301 (8.7%)</td>
<td>4.7</td>
<td>RGL</td>
<td>0</td>
<td>1.5 (1.0–2.1)</td>
<td>2.6 (1.2–6.1)</td>
<td>1.3 (0.9–2.1)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr25-2042018812469645">Hassing <italic>et al.</italic> [2002]</xref></td>
<td>Sweden</td>
<td>84</td>
<td>34</td>
<td>702 (15.4%)</td>
<td>6.0</td>
<td>History</td>
<td>0</td>
<td>1.2 (0.8–1.7)</td>
<td>2.5 (1.4–4.8)</td>
<td>0.8 (0.5–1.5)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr31-2042018812469645">Luchsinger <italic>et al.</italic> [2001]</xref></td>
<td>USA</td>
<td>76</td>
<td>32</td>
<td>1138 (20.3%)</td>
<td>5.5</td>
<td>History</td>
<td>37</td>
<td>-</td>
<td>3.4 (1.7–6.9)</td>
<td>2.0 (1.4–2.9)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2042018812469645">
<label>*</label>
<p>Risk following adjustment for vascular risk factors.</p></fn>
<fn id="table-fn2-2042018812469645"><p>CI, confidence interval; FGL, fasting glucose level; FU, years of follow up; OGTT, oral glucose tolerance test.</p></fn>
</table-wrap-foot></table-wrap>
</sec>
<sec id="section3-2042018812469645">
<title>Diabetes and mild cognitive impairment</title>
<p>Mild cognitive impairment (MCI) has been proposed as a predementia state that might identify individuals at increased risk for progression to dementia [<xref ref-type="bibr" rid="bibr41-2042018812469645">Petersen <italic>et al.</italic> 2009</xref>]. Since first being proposed, there has been considerable debate and controversy about its definitional constraints and prognostic utility [<xref ref-type="bibr" rid="bibr43-2042018812469645">Ritchie and Touchon, 2000</xref>; <xref ref-type="bibr" rid="bibr57-2042018812469645">Whitehouse, 2007</xref>]. A number of studies suggest that diabetes is associated with a 1.5-fold increased risk of developing amnestic MCI or nonamnestic MCI [<xref ref-type="bibr" rid="bibr30-2042018812469645">Luchsinger <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr62-2042018812469645">Yaffe <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr49-2042018812469645">Solfrizzi <italic>et al.</italic> 2004</xref>]. The difficulty in interpreting these studies with relation to diabetes is that MCI is likely to represent a number of heterogeneous disorders rather than a condition on a single disease-severity spectrum.</p>
</sec>
<sec id="section4-2042018812469645">
<title>Diabetes and cognitive function</title>
<p>Consistent with observational studies showing increased risk of cognitive impairment, longitudinal studies have also shown that type 2 diabetes is associated with cognitive decline in some [<xref ref-type="bibr" rid="bibr11-2042018812469645">Christman <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr15-2042018812469645">Elias <italic>et al.</italic> 1997</xref>; <xref ref-type="bibr" rid="bibr16-2042018812469645">Espeland <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr18-2042018812469645">Fischer <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr20-2042018812469645">Gregg <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr21-2042018812469645">Grodstein <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr24-2042018812469645">Hassing <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr37-2042018812469645">Okereke <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr61-2042018812469645">Yaffe <italic>et al.</italic> 2004</xref>, <xref ref-type="bibr" rid="bibr63-2042018812469645">2012</xref>] but not all studies [<xref ref-type="bibr" rid="bibr55-2042018812469645">van den Berg <italic>et al.</italic> 2010</xref>]. A number of studies evaluating specific cognitive domains prospectively have demonstrated performance declines in important domains that might impact on independent diabetes self care, specifically memory [<xref ref-type="bibr" rid="bibr15-2042018812469645">Elias <italic>et al.</italic> 1997</xref>; <xref ref-type="bibr" rid="bibr21-2042018812469645">Grodstein <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr24-2042018812469645">Hassing <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr37-2042018812469645">Okereke <italic>et al.</italic> 2008</xref>], executive function [<xref ref-type="bibr" rid="bibr11-2042018812469645">Christman <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr18-2042018812469645">Fischer <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr21-2042018812469645">Grodstein <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr37-2042018812469645">Okereke <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr61-2042018812469645">Yaffe <italic>et al.</italic> 2004</xref>], language [<xref ref-type="bibr" rid="bibr21-2042018812469645">Grodstein <italic>et al.</italic> 2001</xref>, <xref ref-type="bibr" rid="bibr37-2042018812469645">Okereke <italic>et al.</italic> 2008</xref>] information processing speed [<xref ref-type="bibr" rid="bibr11-2042018812469645">Christman <italic>et al.</italic> 2011</xref>, <xref ref-type="bibr" rid="bibr18-2042018812469645">Fischer <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr20-2042018812469645">Gregg <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr25-2042018812469645">Hassing <italic>et al.</italic> 2002</xref>], verbal memory [<xref ref-type="bibr" rid="bibr16-2042018812469645">Espeland <italic>et al.</italic> 2011</xref>], and abstract reasoning. [<xref ref-type="bibr" rid="bibr15-2042018812469645">Elias <italic>et al.</italic> 1997</xref>].</p>
<p>As a whole, these studies have substantial variations in cohort size, selection biases, the rigour of diabetes ascertainment and, as for dementia, possibly under represent the full impact of diabetes on cognition. Another significant limitation is the frequent lack of consideration of important covariates. For example, only selected studies adjusted for hypertension [<xref ref-type="bibr" rid="bibr15-2042018812469645">Elias <italic>et al.</italic> 1997</xref>; <xref ref-type="bibr" rid="bibr18-2042018812469645">Fischer <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr20-2042018812469645">Gregg <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr21-2042018812469645">Grodstein <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr37-2042018812469645">Okereke <italic>et al.</italic> 2008</xref>], education [<xref ref-type="bibr" rid="bibr15-2042018812469645">Elias <italic>et al.</italic> 1997</xref>; <xref ref-type="bibr" rid="bibr20-2042018812469645">Gregg <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr21-2042018812469645">Grodstein <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr24-2042018812469645">Hassing <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr37-2042018812469645">Okereke <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr61-2042018812469645">Yaffe <italic>et al.</italic> 2004</xref>], lipids [<xref ref-type="bibr" rid="bibr37-2042018812469645">Okereke <italic>et al.</italic> 2008</xref>], vascular disease [<xref ref-type="bibr" rid="bibr15-2042018812469645">Elias <italic>et al.</italic> 1997</xref>; <xref ref-type="bibr" rid="bibr20-2042018812469645">Gregg <italic>et al.</italic> 2000</xref>], and mood [<xref ref-type="bibr" rid="bibr55-2042018812469645">van den Berg <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr61-2042018812469645">Yaffe <italic>et al.</italic> 2004</xref>] and no published study has included all these important covariates into the analyses thus far.</p>
</sec>
<sec id="section5-2042018812469645">
<title>Diabetes and brain structure</title>
<p>Structural brain changes are reported in observational studies of older people with type 2 diabetes. As might be expected with increased vascular risk, cross-sectional studies report more frequent structural brain lesions [<xref ref-type="bibr" rid="bibr33-2042018812469645">Manschot <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr54-2042018812469645">Tiehuis <italic>et al.</italic> 2008</xref>], greater cortical atrophy [<xref ref-type="bibr" rid="bibr34-2042018812469645">Manschot <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr45-2042018812469645">Schmidt <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr54-2042018812469645">Tiehuis <italic>et al.</italic> 2008</xref>] and more numerate white matter hyperintensities [<xref ref-type="bibr" rid="bibr34-2042018812469645">Manschot <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr54-2042018812469645">Tiehuis <italic>et al.</italic> 2008</xref>] in people with diabetes compared with normoglycaemic controls. These studies have found relationships between these structural abnormalities and underlying hypertension and vascular disease [<xref ref-type="bibr" rid="bibr33-2042018812469645">Manschot <italic>et al.</italic> 2007</xref>], but also diabetes-specific parameters such as diabetes duration and fasting glucose levels [<xref ref-type="bibr" rid="bibr54-2042018812469645">Tiehuis <italic>et al.</italic> 2008</xref>]. Longitudinal observation studies are sparse and show a greater increase in lateral ventricular volume in diabetes at 4 years compared with controls [<xref ref-type="bibr" rid="bibr13-2042018812469645">de Bresser <italic>et al.</italic> 2010</xref>]. Studies of brain volume have focused on total brain volume or surrogates; as yet, there are no published data on the potential effects of diabetes on brain regions associated with memory and executive function.</p>
</sec>
<sec id="section6-2042018812469645">
<title>Impaired fasting glucose</title>
<p>The impact of prediabetic glucose disorders [impaired fasting glucose (IFG) and impaired glucose tolerance] on cognition is not clear. IFG in particular is common in older people. There are inconsistent data from longitudinal studies reporting declines in processing speed, executive function and verbal memory [<xref ref-type="bibr" rid="bibr17-2042018812469645">Euser <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr61-2042018812469645">Yaffe <italic>et al.</italic> 2004</xref>, <xref ref-type="bibr" rid="bibr64-2042018812469645">2007</xref>]. One study has examined the impact of fasting glucose over 4 years on hippocampal and amygdala volumes, restricted to blood glucose levels under 6.1 mmol/liter [<xref ref-type="bibr" rid="bibr10-2042018812469645">Cherbuin <italic>et al.</italic> 2012</xref>]. High fasting glucose levels (in the range considered ‘impaired’) was associated with atrophy of these regions, accounting for up to 10% of the change, after accounting for the effects of a number of important covariates. Further studies are awaited to clarify whether IFG in older people adversely affects brain structure and function.</p>
</sec>
<sec id="section7-2042018812469645">
<title>Pathogenesis</title>
<p>The specific mechanisms that mediate cognitive decline in diabetes are not clear. Macrovascular pathways may link hyperglycaemia, hyperlipidaemia, hypertension and low-grade systemic inflammation to structural changes, brain volume loss and cognitive decline, as has been proposed elsewhere [<xref ref-type="bibr" rid="bibr27-2042018812469645">Kloppenborg <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr42-2042018812469645">Reijmer <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr52-2042018812469645">Strachan <italic>et al.</italic> 2011</xref>].</p>
<p>Additional microvascular pathways are also supported. Increasing severity of diabetic retinopathy has been cross-sectionally associated with lower verbal fluency, mental flexibility and processing speed in men but not women [<xref ref-type="bibr" rid="bibr14-2042018812469645">Ding <italic>et al.</italic> 2010</xref>]. Retinopathy has also been associated with the 10-year decline in verbal fluency and processing speed, though this relationship was not restricted to diabetic retinopathy, but was also found with hypertensive retinopathy [<xref ref-type="bibr" rid="bibr29-2042018812469645">Lesage <italic>et al.</italic> 2009</xref>]. The findings suggest that cerebral microangiopathy, as reflected in retinopathy, contributes to structural brain changes and ensuing cognitive decline.</p>
<p>The association of hypoglycaemia with cognitive decline and dementia risk has been examined, with inconsistent results. Severe hypoglycaemia was not associated with cognitive decline, but individuals with dementia appeared to be at risk of future severe hypoglycaemia in one study [<xref ref-type="bibr" rid="bibr8-2042018812469645">Bruce <italic>et al.</italic> 2009</xref>]. In contrast, another study suggested hypoglycaemia frequency and severity appeared to increase risk of dementia [<xref ref-type="bibr" rid="bibr58-2042018812469645">Whitmer <italic>et al.</italic> 2009</xref>]. These discordant results from two large type 2 diabetes cohorts indicate the care required in evaluating cohorts prospectively, since it might be expected that older individuals with baseline cognitive dysfunction may already be on a dementia trajectory and are more likely to make decisions that increase hypoglycaemia risk, such as missing a meal or making an inappropriate medication adjustment.</p>
<p>Genetic factors might impact or mediate the effect of diabetes on cognition. The apolipoprotein E ϵ4 genotype, known to increase the risk of Alzheimer’s disease, has been evaluated in several studies, with a diabetes–genotype interaction for cognitive decline suggested in some [<xref ref-type="bibr" rid="bibr6-2042018812469645">Blair <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr22-2042018812469645">Haan <italic>et al.</italic> 1999</xref>], but not consistently [<xref ref-type="bibr" rid="bibr26-2042018812469645">Kanaya <italic>et al.</italic> 2004</xref>].</p>
<p>Inflammatory mediators are also implicated. Diabetes and obesity are associated with low-grade systemic inflammation. Inflammation increases risk of vascular disease, but may also have a direct effect on the pathogenesis of cognitive decline in diabetes, as suggested by increased inflammation in the brain in dementia [<xref ref-type="bibr" rid="bibr23-2042018812469645">Halliday <italic>et al.</italic> 2000</xref>]. Circulating inflammatory cytokines have been implicated in cognitive decline [<xref ref-type="bibr" rid="bibr46-2042018812469645">Schram <italic>et al.</italic> 2007</xref>]; however, few studies have examined the impact of inflammatory cytokines on cognitive decline in diabetes. One study reported that higher levels of C-reactive protein, interleukin 6 and tumour necrosis factor were associated with lower cognitive performance cross sectionally [<xref ref-type="bibr" rid="bibr35-2042018812469645">Marioni <italic>et al.</italic> 2010</xref>]. Prospective studies examining the associations between circulating inflammatory markers and cognition in diabetes are awaited.</p>
<p>Other hormonal factors of interest in the pathogenesis of cognitive decline in diabetes include relative insulin deficiency [<xref ref-type="bibr" rid="bibr47-2042018812469645">Sima, 2010</xref>; <xref ref-type="bibr" rid="bibr12-2042018812469645">Craft and Watson, 2004</xref>] and glucocorticoid excess [<xref ref-type="bibr" rid="bibr52-2042018812469645">Strachan <italic>et al.</italic> 2011</xref>]. Insulin is anabolic in most tissues. Early studies have shown that chronic hyperinsulinism downregulates insulin receptors at the blood–brain barrier, with reduced brain insulin transport [<xref ref-type="bibr" rid="bibr56-2042018812469645">Wallum <italic>et al.</italic> 1987</xref>]. In rodents, insulin receptors are found in the hippocampus [<xref ref-type="bibr" rid="bibr48-2042018812469645">Singh <italic>et al.</italic> 1997</xref>] and insulin enhances memory and learning [<xref ref-type="bibr" rid="bibr39-2042018812469645">Park <italic>et al.</italic> 2000</xref>]. Readers are referred to comprehensive reviews of the role of insulin in the brain [<xref ref-type="bibr" rid="bibr47-2042018812469645">Sima, 2010</xref>; <xref ref-type="bibr" rid="bibr12-2042018812469645">Craft and Watson, 2004</xref>]. Perturbations in brain insulin levels, signal transduction and action in the brain may link with cerebral vascular dysfunction, but also with inflammation, cellular oxidative stress and, critically, impaired neuronal repair. Further research in this area is likely to inform the area of cognitive decline in diabetes, but will need to rely on animal studies.</p>
</sec>
<sec id="section8-2042018812469645">
<title>Translation of the evidence to clinical practice</title>
<p>Diabetes care focuses on informed independent patient self care to achieve glycaemic targets and minimize vascular risk. Obviously, intact cognition is required to direct diabetes self care in the multiple comorbidities that often accompany diabetes. Annual screening for complications, the standard for diabetes care, does not evaluate cognition, even in older people in whom cognitive decline might be expected. The evidence presented above purports the question: should we consider another end-organ in diabetes complication assessment, the ‘brain’ or a ‘central neuropathy’? The evidence presented above indicates the brain is adversely affected in diabetes, not only by vascular disease and atherothrombotic events, but also by loss of brain volume longitudinally, associated with loss of cognitive abilities in executive function, information processing and memory.</p>
<p>The intactness of these important functional domains is critical for the ongoing safety of independent self care expected in people with type 2 diabetes. We expect our patients to make informed and immediate responses to blood glucose elevations and hypoglycaemia, often with decisions about medication or insulin dose adjustment. For example, ‘I have a virus and my sugars are high, I need to increase my medication or insulin dose.’ ‘I am low, I have checked my sugar to confirm this and need to eat 6 jelly beans, and then retest my sugar.’ We expect our patients to not only operate glucose monitoring equipment (‘where do I switch it on again?’) but problem solve when it malfunctions or readings appear inaccurate: ‘Was there enough blood on the strip?’ ‘Are the strips in date?’ ‘Is this a battery malfunction?’ We expect our patients to negotiate complex dietary instructions, discern increasingly opaque food labels and marketing claims: ‘It says low fat, so it must be ok.’ ‘It is low GI, so I can eat it freely.’ ‘This fruit juice says “No Added Sugar”, so it is fine to drink it all.’ These internal dialogues are commonly reported by patients and indicate that the terrain people with diabetes negotiate is fraught with decision-making pitfalls. Obviously sound and consistent diabetes education helps inform these decisions and may promote and maintain appropriate decision making in an assumed paradigm in which learning and decision making are retained. With the increased risk of cognitive impairment, can we assume that, even when self-care skill sets have been appropriate for some years, our patients will continue to execute these with equal accuracy as they age? Should we be assessing our patients’ diabetes care decision-making more formally? Should cognitive assessment form a part of the annual complication screening in people over 70 years? If so, is the Mini Mental State Examination [<xref ref-type="bibr" rid="bibr19-2042018812469645">Folstein <italic>et al.</italic> 1975</xref>] or a similar screening instrument sufficient, or should more formal assessment be undertaken of cognitive domains involved in diabetes self care, such as executive function and memory? Depression, which is frequent in diabetes, requires active exclusion, but what is the optimal tool to be applied in clinical practice in the elderly?</p>
<p>If cognitive impairment or decline is detected, what intervention is required? Clearly optimizing vascular risk factor management is imperative, but so is reviewing the safety of self-directed diabetes care. This may be examined by at-consultation examination of decision making and establishing safe pathways, supported by education but perhaps supplemented with written instructions and visual supports. As yet, there are no randomized studies to show these strategies are effective or prevent errors in decision making, but they seem ‘common sense’. Medication regimens in diabetes might also need to be simplified to minimize medication-related hypoglycaemia risk and reduce the complexity associated with diet and equipment. Further, additional ‘one-to-one’ support services may be necessary, along with <italic>ad hoc</italic> and perhaps more frequent routine reviews. Family and patient advocates may also benefit from needs-specific diabetes education.</p>
<p>Randomized interventions of intensive glucose lowering have reported changes in cognition and brain structure over 40 months (ACCORD-MIND). While tight glycaemic control was associated with greater total brain volume at study end, there was no functional benefit, as assessed by measures of cognition [<xref ref-type="bibr" rid="bibr28-2042018812469645">Launer <italic>et al.</italic> 2011</xref>]. Coupled with ACCORD’s unexpected findings of increased mortality with tight glycaemic control, it would not appear that tight glucose control to merely preserve brain volume (particularly without cognitive preservation) is justified.</p>
<p>Whether the loss of brain tissue and cognitive function are explained by direct toxic effects of glucose or is mediated by other metabolic, lipid or inflammatory markers that are altered in diabetes requires further study, to understand pathogenesis and how these effects might be attenuated. Until then, it is the responsibility of clinicians involved in the care of older people with diabetes to detect cognitive decline and make appropriate treatment regimen alterations to minimise harm.</p>
</sec>
<sec id="section9-2042018812469645" sec-type="conclusions">
<title>Conclusion</title>
<p>Type 2 diabetes impacts adversely on cognition, at least in part due to macrovascular disease, microvascular changes, hyperlipidaemia, alterations in insulin homeostasis and inflammation. Diabetes care in older people requires monitoring for cognitive decline and modulation of diabetes self care and treatment targets as is appropriate for each individual’s situation. Our benchmark of care should ensure that treatment regimens minimize hypoglycaemia and vascular risk. The self-care regimen should be appropriately tailored to each individual’s cognitive strengths and sufficient clinical support should be offered. Clarification of the pathogenesis of cognitive decline in older people with type 2 diabetes will provide opportunities for minimization of the cognitive decline in this group.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflicts of interest in preparing this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arvanitakis</surname><given-names>Z.</given-names></name>
<name><surname>Wilson</surname><given-names>R.</given-names></name>
<name><surname>Bienias</surname><given-names>J.</given-names></name>
<name><surname>Evans</surname><given-names>D.</given-names></name>
<name><surname>Bennett</surname><given-names>D.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function</article-title>. <source>Arch Neurol</source> <volume>61</volume>: <fpage>661</fpage>–<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr2-2042018812469645">
<citation citation-type="book"><collab>Alzheimer’s Disease International</collab> (<year>2011</year>) <source>World Alzheimer Report 2011</source>. <person-group person-group-type="editor">
<name><surname>Prince</surname><given-names>M.</given-names></name>
<name><surname>Bryce</surname><given-names>R.</given-names></name>
<name><surname>Ferri</surname><given-names>C.</given-names></name>
</person-group> (eds). <publisher-loc>London</publisher-loc>: <publisher-name>Alzheimer’s Disease International</publisher-name>.</citation>
</ref>
<ref id="bibr3-2042018812469645">
<citation citation-type="book"><collab>American Psychiatric Association</collab> (<year>1980</year>) <source>Diagnostic and Statistical Manual of Mental Disorders</source>, <edition>3rd ed.</edition>
<publisher-loc>Washington DC</publisher-loc>: <publisher-name>APA</publisher-name>.</citation>
</ref>
<ref id="bibr4-2042018812469645">
<citation citation-type="book"><collab>American Psychiatric Association</collab> (<year>1994</year>) <source>Diagnostic and Statistical Manual of Mental Disorders</source>, <edition>4th ed.</edition>
<publisher-loc>Washington DC</publisher-loc>: <publisher-name>APA</publisher-name>.</citation>
</ref>
<ref id="bibr5-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Biessels</surname><given-names>G.</given-names></name>
<name><surname>Staekenborg</surname><given-names>S.</given-names></name>
<name><surname>Brunner</surname><given-names>E.</given-names></name>
<name><surname>Brayne</surname><given-names>C.</given-names></name>
<name><surname>Scheltens</surname><given-names>P.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Risk of dementia in diabetes mellitus: a systematic review</article-title>. <source>Lancet Neurol</source> <volume>5</volume>: <fpage>64</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr6-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blair</surname><given-names>C.</given-names></name>
<name><surname>Folsom</surname><given-names>A.</given-names></name>
<name><surname>Knopman</surname><given-names>D.</given-names></name>
<name><surname>Bray</surname><given-names>M.</given-names></name>
<name><surname>Mosley</surname><given-names>T.</given-names></name>
<name><surname>Boerwinkle</surname><given-names>E.</given-names></name>
</person-group> (<year>2005</year>) <article-title>APOE genotype and cognitive decline in a middle-aged cohort</article-title>. <source>Neurology</source> <volume>64</volume>: <fpage>268</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr7-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brayne</surname><given-names>C.</given-names></name>
<name><surname>Gill</surname><given-names>C.</given-names></name>
<name><surname>Huppert</surname><given-names>F.</given-names></name>
<name><surname>Barkley</surname><given-names>C.</given-names></name>
<name><surname>Gehlhaar</surname><given-names>E.</given-names></name>
<name><surname>Girling</surname><given-names>D.</given-names></name>
<etal/></person-group>. (<year>1998</year>) <article-title>Vascular risks and incident dementia: results from a cohort study of the very old</article-title>. <source>Dement Geriatr Cogn Disord</source> <volume>9</volume>: <fpage>175</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr8-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bruce</surname><given-names>D.</given-names></name>
<name><surname>Davis</surname><given-names>W.</given-names></name>
<name><surname>Casey</surname><given-names>G.</given-names></name>
<name><surname>Clarnette</surname><given-names>R.</given-names></name>
<name><surname>Brown</surname><given-names>S.</given-names></name>
<name><surname>Jacobs</surname><given-names>I.</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study</article-title>. <source>Diabetologia</source> <volume>52</volume>: <fpage>1808</fpage>–<lpage>1815</lpage>.</citation>
</ref>
<ref id="bibr9-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bucht</surname><given-names>G.</given-names></name>
<name><surname>Adolfsson</surname><given-names>R.</given-names></name>
<name><surname>Lithner</surname><given-names>F.</given-names></name>
<name><surname>Winblad</surname><given-names>B.</given-names></name>
</person-group> (<year>1983</year>) <article-title>Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type</article-title>. <source>Acta Med Scand</source> <volume>213</volume>: <fpage>387</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr10-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cherbuin</surname><given-names>N.</given-names></name>
<name><surname>Sacdev</surname><given-names>P.</given-names></name>
<name><surname>Anstey</surname><given-names>K.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Higher fasting plasma glucose is associated with hippocampal atrophy</article-title>. <source>Neurology</source> <volume>79</volume>: <fpage>1019</fpage>–<lpage>1026</lpage>.</citation>
</ref>
<ref id="bibr11-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christman</surname><given-names>A.</given-names></name>
<name><surname>Matsushita</surname><given-names>K.</given-names></name>
<name><surname>Gottesman</surname><given-names>R.</given-names></name>
<name><surname>Mosley</surname><given-names>T.</given-names></name>
<name><surname>Lonso</surname><given-names>A.</given-names></name>
<name><surname>Coresh</surname><given-names>J.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study</article-title>. <source>Diabetologia</source> <volume>54</volume>: <fpage>1645</fpage>–<lpage>1652</lpage>.</citation>
</ref>
<ref id="bibr12-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Craft</surname><given-names>S.</given-names></name>
<name><surname>Watson</surname><given-names>G.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Insulin and neurodegenerative disease: shared and specific mechanisms</article-title>. <source>Lancet Neurol</source> <volume>3</volume>: <fpage>169</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr13-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Bresser</surname><given-names>J.</given-names></name>
<name><surname>Tiehuis</surname><given-names>A.</given-names></name>
<name><surname>Van Den Berg</surname><given-names>E.</given-names></name>
<name><surname>Reijmer</surname><given-names>Y.</given-names></name>
<name><surname>Jongen</surname><given-names>C.</given-names></name>
<name><surname>Kappelle</surname><given-names>L.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source> <volume>33</volume>: <fpage>1309</fpage>–<lpage>1314</lpage>.</citation>
</ref>
<ref id="bibr14-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ding</surname><given-names>J.</given-names></name>
<name><surname>Strachan</surname><given-names>M.</given-names></name>
<name><surname>Reynolds</surname><given-names>R.</given-names></name>
<name><surname>Frier</surname><given-names>B.</given-names></name>
<name><surname>Deary</surname><given-names>I.</given-names></name>
<name><surname>Fowkes</surname><given-names>F.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study</article-title>. <source>Diabetes</source> <volume>59</volume>: <fpage>2883</fpage>–<lpage>2889</lpage>.</citation>
</ref>
<ref id="bibr15-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elias</surname><given-names>P.</given-names></name>
<name><surname>Elias</surname><given-names>M.</given-names></name>
<name><surname>D’Agostino</surname><given-names>R.</given-names></name>
<name><surname>Cupples</surname><given-names>L.</given-names></name>
<name><surname>Wilson</surname><given-names>P.</given-names></name>
<name><surname>Silbershatz</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>1997</year>) <article-title>NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study</article-title>. <source>Diabetes Care</source> <volume>20</volume>: <fpage>1388</fpage>–<lpage>1395</lpage>.</citation>
</ref>
<ref id="bibr16-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Espeland</surname><given-names>M.</given-names></name>
<name><surname>Miller</surname><given-names>M.</given-names></name>
<name><surname>Goveas</surname><given-names>J.</given-names></name>
<name><surname>Hogan</surname><given-names>P.</given-names></name>
<name><surname>Coker</surname><given-names>L.</given-names></name>
<name><surname>Williamson</surname><given-names>J.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Cognitive function and fine motor speed in older women with diabetes mellitus: results from the women’s health initiative study of cognitive aging</article-title>. <source>J Womens Health (Larchmt)</source> <volume>20</volume>: <fpage>1435</fpage>–<lpage>1443</lpage>.</citation>
</ref>
<ref id="bibr17-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Euser</surname><given-names>S.</given-names></name>
<name><surname>Sattar</surname><given-names>N.</given-names></name>
<name><surname>Witteman</surname><given-names>J.</given-names></name>
<name><surname>Bollen</surname><given-names>E.</given-names></name>
<name><surname>Sijbrands</surname><given-names>E.</given-names></name>
<name><surname>Hofman</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study</article-title>. <source>Diabetes</source> <volume>59</volume>: <fpage>1601</fpage>–<lpage>1607</lpage>.</citation>
</ref>
<ref id="bibr18-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>A.</given-names></name>
<name><surname>De Frias</surname><given-names>C.</given-names></name>
<name><surname>Yeung</surname><given-names>S.</given-names></name>
<name><surname>Dixon</surname><given-names>R.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Short-term longitudinal trends in cognitive performance in older adults with type 2 diabetes</article-title>. <source>J Clin Exp Neuropsychol</source> <volume>31</volume>: <fpage>809</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr19-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Folstein</surname><given-names>M.</given-names></name>
<name><surname>Folstein</surname><given-names>S.</given-names></name>
<name><surname>McHugh</surname><given-names>P.</given-names></name>
</person-group> (<year>1975</year>) <article-title>‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician</article-title>. <source>J Psychiatr Res</source> <volume>12</volume>: <fpage>189</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr20-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gregg</surname><given-names>E.</given-names></name>
<name><surname>Yaffe</surname><given-names>K.</given-names></name>
<name><surname>Cauley</surname><given-names>J.</given-names></name>
<name><surname>Rolka</surname><given-names>D.</given-names></name>
<name><surname>Blackwell</surname><given-names>T.</given-names></name>
<name><surname>Narayan</surname><given-names>K.</given-names></name>
<name><surname>Cummings</surname><given-names>S.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group</article-title>. <source>Arch Intern Med</source> <volume>160</volume>: <fpage>174</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr21-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grodstein</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Wilson</surname><given-names>R.</given-names></name>
<name><surname>Manson</surname><given-names>J.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Type 2 diabetes and cognitive function in community-dwelling elderly women</article-title>. <source>Diabetes Care</source> <volume>24</volume>: <fpage>1060</fpage>–<lpage>1065</lpage>.</citation>
</ref>
<ref id="bibr22-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haan</surname><given-names>M.</given-names></name>
<name><surname>Shemanski</surname><given-names>L.</given-names></name>
<name><surname>Jagust</surname><given-names>W.</given-names></name>
<name><surname>Manolio</surname><given-names>T.</given-names></name>
<name><surname>Kuller</surname><given-names>L.</given-names></name>
</person-group> (<year>1999</year>) <article-title>The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons</article-title>. <source>JAMA</source> <volume>282</volume>: <fpage>40</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr23-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Halliday</surname><given-names>G.</given-names></name>
<name><surname>Robinson</surname><given-names>S.</given-names></name>
<name><surname>Shepherd</surname><given-names>C.</given-names></name>
<name><surname>Kril</surname><given-names>J.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms</article-title>. <source>Clin Exp Pharmacol Physiol</source> <volume>27</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr24-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hassing</surname><given-names>L.</given-names></name>
<name><surname>Grant</surname><given-names>M.</given-names></name>
<name><surname>Hofer</surname><given-names>S.</given-names></name>
<name><surname>Pedersen</surname><given-names>N.</given-names></name>
<name><surname>Nilsson</surname><given-names>S.</given-names></name>
<name><surname>Berg</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2004</year>) <article-title>Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study</article-title>. <source>J Int Neuropsychol Soc</source> <volume>10</volume>: <fpage>599</fpage>–<lpage>607</lpage>.</citation>
</ref>
<ref id="bibr25-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hassing</surname><given-names>L.</given-names></name>
<name><surname>Johansson</surname><given-names>B.</given-names></name>
<name><surname>Nilsson</surname><given-names>S.</given-names></name>
<name><surname>Berg</surname><given-names>S.</given-names></name>
<name><surname>Pedersen</surname><given-names>N.</given-names></name>
<name><surname>Gatz</surname><given-names>M.</given-names></name>
<name><surname>McClearn</surname><given-names>G.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old</article-title>. <source>Int Psychogeriatr</source> <volume>14</volume>: <fpage>239</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr26-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kanaya</surname><given-names>A.</given-names></name>
<name><surname>Barrett-Connor</surname><given-names>E.</given-names></name>
<name><surname>Gildengorin</surname><given-names>G.</given-names></name>
<name><surname>Yaffe</surname><given-names>K.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort</article-title>. <source>Arch Intern Med</source> <volume>164</volume>: <fpage>1327</fpage>–<lpage>1333</lpage>.</citation>
</ref>
<ref id="bibr27-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kloppenborg</surname><given-names>R.</given-names></name>
<name><surname>Van Den Berg</surname><given-names>E.</given-names></name>
<name><surname>Kappelle</surname><given-names>L.</given-names></name>
<name><surname>Biessels</surname><given-names>G.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review</article-title>. <source>Eur J Pharmacol</source> <volume>585</volume>: <fpage>97</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr28-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Launer</surname><given-names>L.</given-names></name>
<name><surname>Miller</surname><given-names>M.</given-names></name>
<name><surname>Williamson</surname><given-names>J.</given-names></name>
<name><surname>Lazar</surname><given-names>R.</given-names></name>
<name><surname>Gerstein</surname><given-names>H.</given-names></name>
<name><surname>Murray</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy</article-title>. <source>Lancet Neurol</source> <volume>10</volume>: <fpage>969</fpage>–<lpage>977</lpage>.</citation>
</ref>
<ref id="bibr29-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lesage</surname><given-names>S.</given-names></name>
<name><surname>Mosley</surname><given-names>T.</given-names></name>
<name><surname>Wong</surname><given-names>T.</given-names></name>
<name><surname>Szklo</surname><given-names>M.</given-names></name>
<name><surname>Knopman</surname><given-names>D.</given-names></name>
<name><surname>Catellier</surname><given-names>D.</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Retinal microvascular abnormalities and cognitive decline: the ARIC 14-year follow-up study</article-title>. <source>Neurology</source> <volume>73</volume>: <fpage>862</fpage>–<lpage>868</lpage>.</citation>
</ref>
<ref id="bibr30-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luchsinger</surname><given-names>J.</given-names></name>
<name><surname>Reitz</surname><given-names>C.</given-names></name>
<name><surname>Patel</surname><given-names>B.</given-names></name>
<name><surname>Tang</surname><given-names>M.</given-names></name>
<name><surname>Manly</surname><given-names>J.</given-names></name>
<name><surname>Mayeux</surname><given-names>R.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Relation of diabetes to mild cognitive impairment</article-title>. <source>Arch Neurol</source> <volume>64</volume>: <fpage>570</fpage>–<lpage>575</lpage>.</citation>
</ref>
<ref id="bibr31-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luchsinger</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>M.</given-names></name>
<name><surname>Stern</surname><given-names>Y.</given-names></name>
<name><surname>Shea</surname><given-names>S.</given-names></name>
<name><surname>Mayeux</surname><given-names>R.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort</article-title>. <source>Am J Epidemiol</source> <volume>154</volume>: <fpage>635</fpage>–<lpage>641</lpage>.</citation>
</ref>
<ref id="bibr32-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacKnight</surname><given-names>C.</given-names></name>
<name><surname>Rockwood</surname><given-names>K.</given-names></name>
<name><surname>Awalt</surname><given-names>E.</given-names></name>
<name><surname>McDowell</surname><given-names>I.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging</article-title>. <source>Dement Geriatr Cogn Disord</source> <volume>14</volume>: <fpage>77</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr33-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manschot</surname><given-names>S.</given-names></name>
<name><surname>Biessels</surname><given-names>G.</given-names></name>
<name><surname>De Valk</surname><given-names>H.</given-names></name>
<name><surname>Algra</surname><given-names>A.</given-names></name>
<name><surname>Rutten</surname><given-names>G.</given-names></name>
<name><surname>Van Der Grond</surname><given-names>J.</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes</article-title>. <source>Diabetologia</source> <volume>50</volume>: <fpage>2388</fpage>–<lpage>2397</lpage>.</citation>
</ref>
<ref id="bibr34-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manschot</surname><given-names>S.</given-names></name>
<name><surname>Brands</surname><given-names>A.</given-names></name>
<name><surname>Van Der Grond</surname><given-names>J.</given-names></name>
<name><surname>Kessels</surname><given-names>R.</given-names></name>
<name><surname>Algra</surname><given-names>A.</given-names></name>
<name><surname>Kappelle</surname><given-names>L.</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes</article-title>. <source>Diabetes</source> <volume>55</volume>: <fpage>1106</fpage>–<lpage>1113</lpage>.</citation>
</ref>
<ref id="bibr35-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marioni</surname><given-names>R.</given-names></name>
<name><surname>Strachan</surname><given-names>M.</given-names></name>
<name><surname>Reynolds</surname><given-names>R.</given-names></name>
<name><surname>Lowe</surname><given-names>G.</given-names></name>
<name><surname>Mitchell</surname><given-names>R.</given-names></name>
<name><surname>Fowkes</surname><given-names>F.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study</article-title>. <source>Diabetes</source> <volume>59</volume>: <fpage>710</fpage>–<lpage>713</lpage>.</citation>
</ref>
<ref id="bibr36-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McKhann</surname><given-names>G.</given-names></name>
<name><surname>Drachman</surname><given-names>D.</given-names></name>
<name><surname>Folstein</surname><given-names>M.</given-names></name>
<name><surname>Katzman</surname><given-names>R.</given-names></name>
<name><surname>Price</surname><given-names>D.</given-names></name>
<name><surname>Stadlan</surname><given-names>E.</given-names></name>
</person-group> (<year>1984</year>) <article-title>Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease</article-title>. <source>Neurology</source> <volume>34</volume>: <fpage>939</fpage>–<lpage>944</lpage>.</citation>
</ref>
<ref id="bibr37-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okereke</surname><given-names>O.</given-names></name>
<name><surname>Kang</surname><given-names>J.</given-names></name>
<name><surname>Cook</surname><given-names>N.</given-names></name>
<name><surname>Gaziano</surname><given-names>J.</given-names></name>
<name><surname>Manson</surname><given-names>J.</given-names></name>
<name><surname>Buring</surname><given-names>J.</given-names></name>
<name><surname>Grodstein</surname><given-names>F.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults</article-title>. <source>J Am Geriatr Soc</source> <volume>56</volume>: <fpage>1028</fpage>–<lpage>1036</lpage>.</citation>
</ref>
<ref id="bibr38-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ott</surname><given-names>A.</given-names></name>
<name><surname>Stolk</surname><given-names>R.</given-names></name>
<name><surname>Van Harskamp</surname><given-names>F.</given-names></name>
<name><surname>Pols</surname><given-names>H.</given-names></name>
<name><surname>Hofman</surname><given-names>A.</given-names></name>
<name><surname>Breteler</surname><given-names>M.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Diabetes mellitus and the risk of dementia: the Rotterdam Study</article-title>. <source>Neurology</source> <volume>53</volume>: <fpage>1937</fpage>–<lpage>1942</lpage>.</citation>
</ref>
<ref id="bibr39-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>C.</given-names></name>
<name><surname>Seeley</surname><given-names>R.</given-names></name>
<name><surname>Craft</surname><given-names>S.</given-names></name>
<name><surname>Woods</surname><given-names>S.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Intracerebroventricular insulin enhances memory in a passive-avoidance task</article-title>. <source>Physiol Behav</source> <volume>68</volume>: <fpage>509</fpage>–<lpage>514</lpage>.</citation>
</ref>
<ref id="bibr40-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peila</surname><given-names>R.</given-names></name>
<name><surname>Rodriguez</surname><given-names>B.</given-names></name>
<name><surname>Launer</surname><given-names>L.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study</article-title>. <source>Diabetes</source> <volume>51</volume>: <fpage>1256</fpage>–<lpage>1262</lpage>.</citation>
</ref>
<ref id="bibr41-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petersen</surname><given-names>R.</given-names></name>
<name><surname>Roberts</surname><given-names>R.</given-names></name>
<name><surname>Knopman</surname><given-names>D.</given-names></name>
<name><surname>Boeve</surname><given-names>B.</given-names></name>
<name><surname>Geda</surname><given-names>Y.</given-names></name>
<name><surname>Ivnik</surname><given-names>R.</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Mild cognitive impairment: ten years later</article-title>. <source>Arch Neurol</source> <volume>66</volume>: <fpage>1447</fpage>–<lpage>1455</lpage>.</citation>
</ref>
<ref id="bibr42-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reijmer</surname><given-names>Y.</given-names></name>
<name><surname>Van Den Berg</surname><given-names>E.</given-names></name>
<name><surname>Ruis</surname><given-names>C.</given-names></name>
<name><surname>Kappelle</surname><given-names>L.</given-names></name>
<name><surname>Biessels</surname><given-names>G.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Cognitive dysfunction in patients with type 2 diabetes</article-title>. <source>Diabetes Metab Res Rev</source> <volume>26</volume>: <fpage>507</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr43-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ritchie</surname><given-names>K.</given-names></name>
<name><surname>Touchon</surname><given-names>J.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Mild cognitive impairment: conceptual basis and current nosological status</article-title>. <source>Lancet</source> <volume>355</volume>: <fpage>225</fpage>–<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr44-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roman</surname><given-names>G.</given-names></name>
<name><surname>Tatemichi</surname><given-names>T.</given-names></name>
<name><surname>Erkinjuntti</surname><given-names>T.</given-names></name>
<name><surname>Cummings</surname><given-names>J.</given-names></name>
<name><surname>Masdeu</surname><given-names>J.</given-names></name>
<name><surname>Garcia</surname><given-names>J.</given-names></name>
<etal/></person-group>. (<year>1993</year>) <article-title>Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop</article-title>. <source>Neurology</source> <volume>43</volume>: <fpage>250</fpage>–<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr45-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>R.</given-names></name>
<name><surname>Launer</surname><given-names>L.</given-names></name>
<name><surname>Nilsson</surname><given-names>L.</given-names></name>
<name><surname>Pajak</surname><given-names>A.</given-names></name>
<name><surname>Sans</surname><given-names>S.</given-names></name>
<name><surname>Berger</surname><given-names>K.</given-names></name>
<etal/></person-group>. (<year>2004</year>) <article-title>Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study</article-title>. <source>Diabetes</source> <volume>53</volume>: <fpage>687</fpage>–<lpage>692</lpage>.</citation>
</ref>
<ref id="bibr46-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schram</surname><given-names>M.</given-names></name>
<name><surname>Euser</surname><given-names>S.</given-names></name>
<name><surname>De Craen</surname><given-names>A.</given-names></name>
<name><surname>Witteman</surname><given-names>J.</given-names></name>
<name><surname>Frolich</surname><given-names>M.</given-names></name>
<name><surname>Hofman</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Systemic markers of inflammation and cognitive decline in old age</article-title>. <source>J Am Geriatr Soc</source> <volume>55</volume>: <fpage>708</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr47-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sima</surname><given-names>A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Encephalopathies: the emerging diabetic complications</article-title>. <source>Acta Diabetol</source> <volume>47</volume>: <fpage>279</fpage>–<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr48-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>B.</given-names></name>
<name><surname>Rajakumar</surname><given-names>P.</given-names></name>
<name><surname>Eves</surname><given-names>E.</given-names></name>
<name><surname>Rosner</surname><given-names>M.</given-names></name>
<name><surname>Wainer</surname><given-names>B.</given-names></name>
<name><surname>Devaskar</surname><given-names>S.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Insulin gene expression in immortalized rat hippocampal and pheochromocytoma-12 cell lines</article-title>. <source>Regul Pept</source> <volume>69</volume>: <fpage>7</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr49-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solfrizzi</surname><given-names>V.</given-names></name>
<name><surname>Panza</surname><given-names>F.</given-names></name>
<name><surname>Colacicco</surname><given-names>A.</given-names></name>
<name><surname>D’Introno</surname><given-names>A.</given-names></name>
<name><surname>Capurso</surname><given-names>C.</given-names></name>
<name><surname>Torres</surname><given-names>F.</given-names></name>
<etal/></person-group>. (<year>2004</year>) <article-title>Vascular risk factors, incidence of MCI, and rates of progression to dementia</article-title>. <source>Neurology</source> <volume>63</volume>: <fpage>1882</fpage>–<lpage>1891</lpage>.</citation>
</ref>
<ref id="bibr50-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinman</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>John Boscardin</surname><given-names>W.</given-names></name>
<name><surname>Miao</surname><given-names>Y.</given-names></name>
<name><surname>Fung</surname><given-names>K.</given-names></name>
<name><surname>Moore</surname><given-names>K.</given-names></name>
<etal/></person-group>. (<year>2012</year>) <article-title>Patterns of multimorbidity in elderly veterans</article-title>. <source>J Am Geriatr Soc</source> <volume>60</volume>: <fpage>1872</fpage>–<lpage>1880</lpage>.</citation>
</ref>
<ref id="bibr51-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strachan</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>R D Lawrence Lecture 2010. The brain as a target organ in type 2 diabetes: exploring the links with cognitive impairment and dementia</article-title>. <source>Diabet Med</source> <volume>28</volume>: <fpage>141</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr52-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strachan</surname><given-names>M.</given-names></name>
<name><surname>Reynolds</surname><given-names>R.</given-names></name>
<name><surname>Marioni</surname><given-names>R.</given-names></name>
<name><surname>Price</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Cognitive function, dementia and type 2 diabetes mellitus in the elderly</article-title>. <source>Nat Rev Endocrinol</source> <volume>7</volume>: <fpage>108</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr53-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>M.</given-names></name>
<name><surname>Walker</surname><given-names>M.</given-names></name>
<name><surname>Emberson</surname><given-names>J.</given-names></name>
<name><surname>Thomson</surname><given-names>A.</given-names></name>
<name><surname>Lawlor</surname><given-names>D.</given-names></name>
<name><surname>Ebrahim</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>Prevalence of undiagnosed type 2 diabetes and impaired fasting glucose in older British men and women</article-title>. <source>Diabet Med</source> <volume>22</volume>; <fpage>789</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr54-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tiehuis</surname><given-names>A.</given-names></name>
<name><surname>Van Der Graaf</surname><given-names>Y.</given-names></name>
<name><surname>Visseren</surname><given-names>F.</given-names></name>
<name><surname>Vincken</surname><given-names>K.</given-names></name>
<name><surname>Biessels</surname><given-names>G.</given-names></name>
<name><surname>Appelman</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease</article-title>. <source>Stroke</source> <volume>39</volume>: <fpage>1600</fpage>–<lpage>1603</lpage>.</citation>
</ref>
<ref id="bibr55-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Den Berg</surname><given-names>E.</given-names></name>
<name><surname>Reijmer</surname><given-names>Y.</given-names></name>
<name><surname>De Bresser</surname><given-names>J.</given-names></name>
<name><surname>Kessels</surname><given-names>R.</given-names></name>
<name><surname>Kappelle</surname><given-names>L.</given-names></name>
<name><surname>Biessels</surname><given-names>G.</given-names></name>
</person-group> (<year>2010</year>) <article-title>A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus</article-title>. <source>Diabetologia</source> <volume>53</volume>: <fpage>58</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr56-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wallum</surname><given-names>B.</given-names></name>
<name><surname>Taborsky</surname><given-names>G.</given-names><suffix>Jr</suffix></name>
<name><surname>Porte</surname><given-names>D.</given-names><suffix>Jr</suffix></name>
<name><surname>Figlewicz</surname><given-names>D.</given-names></name>
<name><surname>Jacobson</surname><given-names>L.</given-names></name>
<name><surname>Beard</surname><given-names>J.</given-names></name>
<etal/></person-group>. (<year>1987</year>) <article-title>Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man</article-title>. <source>J Clin Endocrinol Metab</source> <volume>64</volume>: <fpage>190</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr57-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitehouse</surname><given-names>P.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Mild cognitive impairment – a confused concept?</article-title> <source>Nat Clin Pract Neurol</source> <volume>3</volume>: <fpage>62</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr58-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitmer</surname><given-names>R.</given-names></name>
<name><surname>Karter</surname><given-names>A.</given-names></name>
<name><surname>Yaffe</surname><given-names>K.</given-names></name>
<name><surname>Quesenberry</surname><given-names>C.</given-names><suffix>Jr</suffix></name>
<name><surname>Selby</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus</article-title>. <source>JAMA</source> <volume>301</volume>: <fpage>1565</fpage>–<lpage>1572</lpage>.</citation>
</ref>
<ref id="bibr59-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolf-Klein</surname><given-names>G.</given-names></name>
<name><surname>Siverstone</surname><given-names>F.</given-names></name>
<name><surname>Brod</surname><given-names>M.</given-names></name>
<name><surname>Levy</surname><given-names>A.</given-names></name>
<name><surname>Foley</surname><given-names>C.</given-names></name>
<name><surname>Termotto</surname><given-names>V.</given-names></name>
<etal/></person-group>. (<year>1988</year>) <article-title>Are Alzheimer patients healthier?</article-title>
<source>J Am Geriatr Soc</source> <volume>36</volume>: <fpage>219</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr60-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>W.</given-names></name>
<name><surname>Qiu</surname><given-names>C.</given-names></name>
<name><surname>Wahlin</surname><given-names>A.</given-names></name>
<name><surname>Winblad</surname><given-names>B.</given-names></name>
<name><surname>Fratiglioni</surname><given-names>L.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study</article-title>. <source>Neurology</source> <volume>63</volume>: <fpage>1181</fpage>–<lpage>1186</lpage>.</citation>
</ref>
<ref id="bibr61-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yaffe</surname><given-names>K.</given-names></name>
<name><surname>Blackwell</surname><given-names>T.</given-names></name>
<name><surname>Kanaya</surname><given-names>A.</given-names></name>
<name><surname>Davidowitz</surname><given-names>N.</given-names></name>
<name><surname>Barrett-Connor</surname><given-names>E.</given-names></name>
<name><surname>Krueger</surname><given-names>K.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Diabetes, impaired fasting glucose, and development of cognitive impairment in older women</article-title>. <source>Neurology</source> <volume>63</volume>: <fpage>658</fpage>–<lpage>663</lpage>.</citation>
</ref>
<ref id="bibr62-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yaffe</surname><given-names>K.</given-names></name>
<name><surname>Blackwell</surname><given-names>T.</given-names></name>
<name><surname>Whitmer</surname><given-names>R.</given-names></name>
<name><surname>Krueger</surname><given-names>K.</given-names></name>
<name><surname>Barrett Connor</surname><given-names>E.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women</article-title>. <source>J Nutr Health Aging</source> <volume>10</volume>: <fpage>293</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr63-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yaffe</surname><given-names>K.</given-names></name>
<name><surname>Falvey</surname><given-names>C.</given-names></name>
<name><surname>Hamilton</surname><given-names>N.</given-names></name>
<name><surname>Schwartz</surname><given-names>A.</given-names></name>
<name><surname>Simonsick</surname><given-names>E.</given-names></name>
<name><surname>Satterfield</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2012</year>) <article-title>Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia</article-title>. <source>Arch Neurol</source> <volume>69</volume>: <fpage>1170</fpage>-<lpage>1175</lpage>.</citation>
</ref>
<ref id="bibr64-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yaffe</surname><given-names>K.</given-names></name>
<name><surname>Haan</surname><given-names>M.</given-names></name>
<name><surname>Blackwell</surname><given-names>T.</given-names></name>
<name><surname>Cherkasova</surname><given-names>E.</given-names></name>
<name><surname>Whitmer</surname><given-names>R.</given-names></name>
<name><surname>West</surname><given-names>N.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging study</article-title>. <source>J Am Geriatr Soc</source> <volume>55</volume>: <fpage>758</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr65-2042018812469645">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshitake</surname><given-names>T.</given-names></name>
<name><surname>Kiyohara</surname><given-names>Y.</given-names></name>
<name><surname>Kato</surname><given-names>I.</given-names></name>
<name><surname>Ohmura</surname><given-names>T.</given-names></name>
<name><surname>Iwamoto</surname><given-names>H.</given-names></name>
<name><surname>Nakayama</surname><given-names>K.</given-names></name>
<etal/></person-group>. (<year>1995</year>) <article-title>Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study</article-title>. <source>Neurology</source> <volume>45</volume>: <fpage>1161</fpage>–<lpage>1168</lpage>.</citation>
</ref></ref-list>
</back>
</article>